ClinicalTrials.gg
TerminatedNCT03320876Updated Apr 21, 2022

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

A Phase 2 interventional study of filgotinib in Psoriatic Arthritis, sponsored by Galapagos NV. Terminated at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-21.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Why this study was terminated
development program for filgotinib for participants with psoriatic arthritis has been stopped

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Arthritis, Psoriatic with a site in Ukraine — none open to participants now, 6 under way, 2 of them phase 3. Arthritis, Psoriatic · Ukraine.

Enrollment
18th of 20
122 · median 389
Started
2017
with 5 others
Phase 2
6 of 22
none open now
Registered
12th of 22
by date
Lead sponsor
3 of 22
Galapagos NV

Among the 22 studies in Arthritis, Psoriatic with a site in Ukraine, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2017, is one of 6 in phase 2, and was the 12th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

None of the 22 studies in Arthritis, Psoriatic with a site in Ukraine is open now. The open studies under Arthritis, Psoriatic, anywhere →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Arthritis, Psoriatic with a site in Ukraine as a file.
02

Study summary

This is a Phase 2, multicenter, open-label, single arm, Long Term Extension (LTE) safety, tolerability and efficacy study of filgotinib in subjects with moderately to severely active PsA. It is estimated that approximately 105 subjects will be rolled-over after they have completed the 16 weeks of double-blind treatment in core study GLPG0634-CL-224. Subjects will be administered filgotinib in this study until filgotinib is registered for PsA or until Week 304, whichever occurs first. The LTE study is concluded with a follow-up visit approximately 4 weeks after the last intake of study treatment.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects who are ≥18 years of age, having completed the 16 weeks of treatment in the qualifying core study GLPG0634-CL-224 and who may benefit from filgotinib long-term treatment according to the investigator's judgment.
  • Male and female subjects of who engage in heterosexual intercourse must agree to continue to use highly effective methods of as described in the protocol.
  • Able and willing to sign the form (ICF), as approved by the Independent Ethics Committee (IEC) and agree to the schedule of assessments.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are deemed not to be benefitting from the study drug based upon lack of improvement or worsening of their symptoms. Local guidelines for subject treatment need to be followed.
  • Persistent abnormal laboratory values associated with the use of the study drug (including and not limited to hematology, liver and renal function values), according to the investigator's clinical judgment.
  • Subjects who discontinued the qualifying core study GLPG0634-CL-224 due to safety or tolerability issues.
  • Subjects who require immunization with live/.
  • Diagnosis of rheumatic disease or inflammatory joint disease other than psoriatic arthritis, except for Sjögren's syndrome.
  • Subjects with symptoms suggestive of uncontrolled hypertension, congestive heart failure, uncontrolled diabetes, cerebrovascular accident, myocardial infarction, unstable angina, unstable arrhythmia or any other cardiovascular condition since the inclusion to the GLPG0634- CL-224 study.
  • Subjects with symptoms suggestive of gastrointestinal tract ulceration and/or active diverticulitis since the inclusion to the GLPG0634-CL-224 study.
  • Subjects with symptoms suggestive of possible lymphoproliferative disease including lymphadenopathy or splenomegaly since the inclusion to the GLPG0634-CL-224 study.
  • Subjects with symptoms suggestive of since the inclusion to the GLPG0634-CL-224 study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    filgotinib

    Drug: filgotinib

Interventions

  • one filgotinib oral tablet once daily.

06

What researchers measure

Primary outcomes

  1. Change in the proportion of subjects with adverse events

    To asses safety and tolerability of filgotinib.

    Time frame: Between entry visit and 4 weeks after the last dose.

Secondary outcomes

  1. Proportion of subjects achieving minimal disease activity (MDA)

    To assess the effect of filgotinib on MDA in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  2. Proportion of subjects achieving American College of Rheumatology 20 (ACR20) response

    To assess the effect of filgotinib on PsA as assessed by ACR20 in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  3. Proportion of subjects achieving ACR50 response

    To assess the effect of filgotinib on PsA as assessed by ACR50 in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  4. Proportion of subjects achieving ACR70 response

    To assess the effect of filgotinib on PsA as assessed by ACR70 in PsA patients

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  5. Proportion of subjects with Psoriatic Arthritis Disease Activity Score (PASDAS) low disease activity (LDA, i.e. PASDAS ≤ 3.2)

    To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  6. Proportion of subjects with PASDAS Very Low Disease Activity (VLDA) (i.e. PASDAS ≤1.9)

    To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  7. Percentage of patients subjects with PASDAS LDA (i.e. PASDAS ≤3.2)

    To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  8. Percentage of patients subjects with PASDAS VLDA (i.e. PASDAS ≤1.9)

    To assess the effect of filgotinib on PsA as assessed by PASDAS in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  9. Change from core baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)

    To assess the effect of filgotinib on PsA as assessed by DAPSA in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  10. Proportion of subjects with DAPSA remission/LDA (DAPSA ≤14)

    To assess the effect of filgotinib on PsA as assessed by DAPSA in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  11. Proportion of subjects with DAPSA remission (DAPSA ≤4)

    To assess the effect of filgotinib on PsA as assessed by DAPSA in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  12. Change from core baseline in Psoriasis Area and Severity Index (PASI)

    To assess the effect of filgotinib on PASI in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  13. Proportion of subjects with PASI50

    To assess the effect of filgotinib on PASI50 in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  14. Proportion of subjects with PASI75

    To assess the effect of filgotinib on PASI75 in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  15. Proportion of subjects with PASI90

    To assess the effect of filgotinib on PASI90 in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  16. Proportion of subjects with PASI100

    To assess the effect of filgotinib on PASI100 in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  17. Change from core baseline in Physician's global assessment of psoriasis

    To assess the affect of filgotinib on Physician's global assessment of psoriasis in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  18. Change from core baseline in Patient's Global Assessment of psoriasis

    To assess the affect of filgotinib on patient's global assessment of psoriasis in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  19. Change from core baseline in modified Nail Psoriasis Area and Severity Index (mNAPSI)

    To assess the effect of filgotinib on mNAPSI in PsA patients assessment of psoriasis in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  20. Change from core baseline in pruritis numeric rating scale (NRS)

    To assess the effect of filgotinib on NRS in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  21. Proportion of subjects achieving a pruritis numeric rating scale (NRS) response(improvement in pruritus NRS score of ≥3)

    To assess the effect of filgotinib on NRS in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  22. Change from core baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index

    To assess the effect of filgotinib on SPARCC enthesitis index in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  23. Change from core baseline in Leeds Dactylitis Index (LDI)

    To assess the effect of filgotinib on Dactilytis in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  24. Change from core baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

    To assess the effect of filgotinib on physical function in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

  25. Change from baseline in Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue scale)

    To assess the effect of filgotinib on FACIT-Fatigue scale in PsA patients.

    Time frame: W4, W52, W100, W148, W172, W196, W220, W244, W268, W292, W304.

  26. Change from core baseline in 36-item Short-Form Health Survey (SF-36)

    To assess the effect of filgotinib on SF-36 in PsA patients

    Time frame: W4, W52, W100, W148, W172, W196, W220, W244, W268, W292, W304.

  27. Change from core baseline in Psoriatic Arthritis Impact of Disease Questionnaire (PsAID).

    To assess the effect of filgotinib on PsAID in PsA patients.

    Time frame: W4, W52, W100, W148, W172, W196, W220, W244, W268, W292, W304.

  28. Change from core baseline in individual components of the ACR response of improvement in multiple disease assessment criteria

    To assess the effect of filgotinib on signs and symptoms of peripheral arthritis and physical function in PsA patients.

    Time frame: At each on-site visit until filgotinib is registered for PsA or until Week 304, whichever occurs first.

07

Study locations

25 sites
  • ULB Hopital Erasme, Service de Rheumatology
    Brussels, Belgium
  • UMHAT "Kaspela", EOOD
    Plovdiv, Bulgaria
  • MHAT - Ruse, AD
    Ruse, Bulgaria
  • UMHAT "SofiaMed", OOD, Block 1
    Sofia, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, Bulgaria
  • CCBR Czech, a.s
    Pardubice, Czechia
  • MEDICAL PLUS s.r.o.
    Uherské Hradiště, Czechia
  • Center for Clinical and Basic Research
    Tallinn, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, Estonia
  • OÜ Innomedica
    Tallinn, Estonia
  • Twoja Przychodnia-Centrum Medyczne Nowa Sol
    Nowa Sól, Poland
  • Ai Centrum Medyczne sp. z o.o. sp.k.
    Poznań, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z, Przychodnia Specjalistyczna
    Toruń, Poland
  • Centrum Medyczne AMED, Warszawa Targowek
    Warsaw, Poland
  • Hospital Universitario de Fuenlabrada, Servicio de Reumatologia
    Fuenlabrada, Spain
  • Hospital Infanta Luisa, Servicio de Reumatologia
    Sevilla, Spain
  • CI of Healthcare Kharkiv CCH #8 Dept of Rheumatology Kharkiv MA of PGE of MOHU, Ch of Cardiology and Funct Diagnostics
    Kharkiv, Ukraine
  • CNI Consultative and Diagnostic Center of Pecherskyi District of Kyiv, Department of Therapy
    Kiev, Ukraine
  • SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU, Unit of Non-coronary HD&Rh
    Kyiv, Ukraine
  • CH of State Border Service of Ukraine (Military Base 2522) Dept of Therapy, D.Halytskyi Lviv NMU, Ch of Family Medicine & Dermatology, Venereology
    L'viv, Ukraine
  • M.V. Sklifosovskyi Poltava RCH Dept of Rheumatology HSEIU UMSA, Ch of Family Medicine and Therapy
    Poltava, Ukraine
  • CI of TRC
    Ternopil', Ukraine
  • M.I. Pyrogov VRCH Dept of Rheumatology M.I. Pyrogov VNMU, Ch of IM #1
    Vinnytsia, Ukraine
  • SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU, Un of Therapy and CRh Dept of Therapy
    Vinnytsia, Ukraine
  • MCIC MC LLC Health Clinic, Unit of Cardiology and Rheumatology
    Vinnytsya, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Jun 2021, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Oct 25, 2017
StartActual
Jul 26, 2017
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Last update
Apr 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03320876
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Jul 26, 2017
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Apr 21, 2022

Study contacts

Vijay Rajendran, MD
study director · Galapagos NV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion